Healthcare Report

Biogen is at 48.03. Most recent news to report regarding it is that last Thursday it initiated Phase II Trial of Galiximab for follicular non-hodgkin's lymphoma. The study is a registrational clinical trial being conducted under a Special Protocol Assessment granted by the U.S. Food and Drug Administration (FDA) in July 2006. Earnings are released Feb 15 th. Merck's earnings fell 58% and Wyeth's rose 17% however both missed Wall Street Estimates. On Jan 23, Pfizer was downgraded by Bear Stearns. JNJ earnings are up 2.53% and Abbott Labs (ABT) were up 5.41%. I will continue to watch Abbot Labs over the next week and see its progress and then may propose a buy. Any thoughts, questions or opinions please let me know.

Liz Hershman